CHEMOTHERAPY MAY. 1988

Similar documents

VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant St

CHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz

CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study

Key words : 7432-S, Oral cephem, Urinary tract infection Fig. 1. Chemical structure of 7432-S.

CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus

VOL.42 S-1

CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX

VOL. 34 S-2 CHEMOTH8RAPY 913

VOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human


Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates

Fig. 1 Chemical structure of DL-8280

CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin

Fig. 1 Chemical structure of norfioxacin (AM-715)

CHEMOTHERAPY JUNE 1986

Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII (45)

Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile

CHEMOTHERAPY

988 CHEMOTHERAPY NOV. 1971




1272 CHEMOTHERAPY MAR. 1975

Fig. 1 Chemical structure of KW-1070

pneumoniae 30, C. freundii 32, E. aerogenes 27, E. cloacae 32, P. mirabilis 31, P. vulgaris 34, M. morganii 32, S. marcescens 31, H. influenzae 27, P.

CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates

epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia

VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )


CHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote

VOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT against standard strains

CHEMOTHERAPY DEC Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus, G; Gaffk

CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin


Table1MIC of BAY o 9867 against standard strains

Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-

Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent

VOL. 23 NO. 3 CHEMOTHERAPY 1379 Table 1 Susceptibility of clinical isolated strains to Tobramycin


Fig.1 Chemical structure of BAY o 9867

2108 CHEMOTHERAPY SEPT Table 1 Antimicrobial spectrum Fig. 1

CHEMOTHERAPY Fig. 1 Body weight changes of pregnant mice treated orally with AM- 715 Day of sestation


VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega



VOL.47 NO.5 Table 1. Susceptibility distribution of Ĉ- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus

coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F


Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone

THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec LVFX 100 mg 3 / mg 2 / LVFX PK PD mg mg 1 1 AUC/MIC

CHEMOTHERAPY SEPT. 1970

Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml


CHEMOTHERAPY


日本化学療法学会雑誌第59巻第5号

CHEMOTHERAPY APR Fig. 2 The inactivation of aminoglycoside antibiotics by PC-904 Fig. 3 Serum concentration of PC-904 (1) Fig. 4 Urinary recover


VOL.42 S-1 methicillin-susceptible Staphylococcus aureus (MSSA), Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli, Klebsiella pneum



CHEMOTHERAPY DEC (NFLX), ofloxacin (OFLX), ciprofloxacin (CPFX) Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecali


400 CHEMOTHERAPY JAN Table 1 Cases of drop outs

VOL. 43 NO. 4



CHEMOTHERAPY

CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical Co.);


CHEMOTHERAPY APR Fig. 1 Chemical structure of cefotetan (CTT, YM09330)

VOL. 20 NO. 5 CHEMOTHERAPY Methoxy-4-sulfanilamidopyrimidine (OS-3376) Sulfadimethoxine (SDM) Table 1. In vitro antibacterial activities of OS-3


Table 1 Classification of female patients with vesical irritating symptom by their signs : Urinary pain with or without other vesical irritability. s


THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec DNA 2, , % 1.65% 1.17% 90% 9 Escherichia coli -

CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Kle

CHEMOTHERAPY OCT Fig. 1 Chemical structure of CVA-K

Table 1. Concentration of ritipenem in plasma, gallbladder tissue and bile after ritipenem acoxil administration (200 mg t.i.d., 3 days) N.D.: not det

CHEMOTHERAPY SEPT. 1991

日本化学療法学会雑誌第65巻第4号

THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium xerosis 10Š, Corynebacterium pseudodiphtheriticum 10Š, Corynebacterium

VOL.39 S-3

Clinical studies on Cef triaxone in the field of oral surgery JIRO SASAKI,*1 MASATAKA UEMATSU,*l AKIHIRO KANEKO,*1 YOSHIHIDE OHTA,*1 KAZUO SHIIKI,*2 T

CHEMOTHERAPY DEC phvlococcus aureus Staphylococcus Enterococcus faecalis Escherichia Klebsiella pneumoniae Serratia marcescens Pseudomonas cepac

CHEMOTHERAPY APR. 1984


Title 神経因性膀胱にともなう排尿障害に対する塩酸ブナゾシンの臨床効果 - 二重盲検比較試験による検討 - 小柳, 知彦 ; 富樫, 正樹 ; 丸, 彰夫 ; 折笠, 精一 ; 相馬, Author(s) 崎, 淳 ; 安田, 耕作 ; 阿曽, 佳郎 ; 本問, 之夫 ; 三宅, 弘厚生 ; 熊




明海大学歯学雑誌　３７‐２／１．秦泉寺

VOL.27 CHEMOT S-1 HERAPY 185 に感 性 を示 して い たが,臨 床 的 に は無 効 で あ った 本 症 る 細 菌学 的 に も検 討 した が,起 炎菌 と考 え られ る細 菌 を 例 で は 基礎 疾 患 と して縦 隔 洞腫 瘍 が あ り,既 に 副 腎

Hisao Takayasu Department of Urology, Faculty of Medicine, University of Tokyo Masaaki Ohkoshi Department of Urology, Tokai University School of Medic

Physical and Psychological Effects of Stressors in Female College Students Reizou Mita*1, Konosuke Tomabechi*1, Isao Yamaguchi*1, Naoko Soeno*1, Shuhe

Some Investigations of Urinary Candidiasis Chujiro YAMAMOTO, M. D., Mitsushi MIZUTANI, M. D. and Tokuro SATO, M. D. From the Department of Urology, Ni

東洋医学雑誌


Transcription:

CHEMOTHERAPY MAY. 1988

CHEMOTHERAPY Fig. 1 Chemical structure

CHEMOTHERAPY MAY. 1988

VOL.36 5-1 CHEMOTHERAPY

CHEMOTHERAPY MAY. 1988

VOL.36 S-1 CHEMOTHERAPY

CHEMOTHERAPY MAY. 1988

VOL.36 S-1 CHEMOTHERAPY

CHEMOTHERAPY MAY. 1988

CHEMOTHERAPY

CHEMOTHERAPY

CHEMOTHERAPY

CHEMOTHERAPY

CHEMOTHERAPY

CHEMOTHERAPY

CHEMOTHERAPY

CHEMOTHERAPY

CHEMOTHERAPY Table 3 Distribution of sex and weight Table 4 Clinical effect classified by duration of administration

CHEMOTHERAPY Table 5 Clinical efficacy classified by diagnosis and daily dose

VOL 36 S- I CHEMOTHERAPY Table 6 Clinical efficacy of CS-807 (physician's assessment) Table 7 Clinical efficacy of CS-807 (attending committee's assessment)

CHEMOTHERAPY MAY, 1988 Table 8 Clinical effect of CS-807 in cases treated with other antibiotics for 3 days or longer with poor result Table 9 Bacteriological efficacy of CS-807 classified by diagnosis

VOL.36 S-1 CHEMOTHERAPY (Monomicrobial) Table 10 Clinical effect of CS-807 classified by clinical isolates (Physician's assessment) Tablet 11 Clinical effect of CS-807 classified by clinical isolates (Physician's assessment) (Polymicrobial)

CHEMOTHERAPY MAY. 1988 (Monomicrobial) Table 12 Bacteriological efficacy of CS-807 classified by clinical isolates (1) (Polymicrobial) Table 13 Bacteriological efficacy of CS-807 classified by clinical isolates (2)

VOL.36 S-1 CHEMOTHERAPY Table 14 MICs of R-3763 against clinical isolates (106 cells/m1)

CHEMOTHERAPY MAY. 1988 Fig. 2 Susceptibility of S. aureus to R.3763 (46 strains 106 cells/ml) Fig. 3 Susceptibility of S. aureus to R-3763 (46 strains 108 cells/ml)

VOL.36 S-1 CHEMOTHERAPY Fig. 4 Susceptibility of S. epidermidis to R-3763 (17 strains 106 cells/ml) Fig. 5 Susceptibility of S. epidermidis to R-3763 (17 strains 108 cells/ml).

CHEMOTHERAPY 2) T. KOMAI, K. FUJIMOTO, M. SEKINE and H. MASUDA: CS-807, a New Orally Active C-ephalosporin. Absorption-excretion Studies in Experimental of the Twenty-Sixth Antimicrobial 1986, New Orleans. Animals., Program and Abstracts Interscience Conference on Agents and Chemotherapy p.205, 3) S. SUGAWARA, M. IWATA, M. TAJIMA, T. MAGARI- BUCHI, H. YANAGISAWA, H. NAKAO, J. KUMAZAWA and S. KUWAHARA: Res. Labs., Sankyo Co., Ltd., CS-807, a New Orally Active Cephalosporin. In vitro and in vivo Antibacterial Activities., Program and Abstracts of the Twenty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy p.205, 1986, New Orleans.

CHEMOTHERAPY 647 CLINICAL APPLICATION OF CS-807, AN ORAL CEPHALOSPORIN ANTIBIOTIC, TO SKIN AND SOFT-TISSUE INFECTIONS ISSEI NAKAYAMA Third Department of Surgery, Nihon University School of Medicine, Tokyo EMIKO YAMAJI, HIROSHI KAWAMURA, HIROSHI KAWAGUCHI Microbiological Section, The Center of Health Science, Nihon University School of Medicine, Tokyo Yozo AKIEDA Department of Surgery, Akieda Hospital, Tokyo TETSUYA WATANABE Department of Surgery, Itabashi Chuo Sogo Hospital, Tokyo TOSHIAKI SUZUKI Department of Surgery, Kanamemachi Hospital, Tokyo KANJI ITOKAWA Department of Surgery, Seya Chuo Hospital KAZUE UENO, KUNITOMO WATANABE, TERUKO KANAZAWA Institute of Anaerobic Bacteriology, School of Medicine, Gifu University, Gifu Clinical study was made of a new oral cephalosporin antibiotic CS-807 on skin and soft tissue infections. Subject diseases were 144 cases of suppurative atheroma, felon, furuncle, carbuncle, subcutaneous abscess, phlegmon, periproctal abscess, lymphadenitis, lymphangitis, wound infection, paronychia, subareolar abscess, suppurative mastitis, suppurative hydradenitis, omphalitis, suppurative folliculitis, etc. Clinical effects judged by the physicians in charge were : excellent - 25 cases ; good - 96 cases ; fair - 17 cases ; and poor - 6 cases out of 144 cases, efficacy rate being 84.0%. On the other hand, clinical effects according to the unified judgement standards were : excellent - 83 cases ; good - 46 cases ; fair - 7 cases ; and poor - 8 cases, efficacy rate being 89.6%. Clinical effects by dose were found as : efficacy rate 80.6% in 200 mg daily dose group and 85.9% in 400 mg group, and stochastically 400 mg group showed superior clinical effect, compared with 200 mg group. In bacteriological study, rate of elimination was seen as 86.9% in 61 cases of single infection and 93% in 57 cases of mixed infection. Clinical effect of this drug on the cases in whom preliminarily-administered drug was ineffective showed results more than good in 12 cases out of 15, efficacy rate being 80%. Regarding adverse effect, there was no case who showed subjective or objective symptom among 144 cases. Investigation of abnormal clinical test value was possible in 1 case but no particular abnormality was observed. As a result of investigating MIC in 179 strains of 36 species, 144 strains (80.4%) out of 179 showed a distribution at a level lower than 3.13 pg/ ml of this drug.

2024 © docsplayer.net プライバシー | 利用規約 | フィードバック